Press Releases
The latest news from StrideBio.
February 4, 2022  •  Research Triangle Park, N.C.
StrideBio Announces Mark Velleca, M.D., Ph.D., as Chief Executive Officer
Research Triangle Park, N.C., February 4, 2022 – StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment ...
October 4, 2021  •  Research Triangle Park, N.C.
StrideBio Announces Achievement of Significant Operational Milestones Supporting Transition of Novel Gene Therapy Pipeline to Clinical Stage
100th team member hired, bolstering internal capabilities from capsid platform to clinic with an emphasis on in-house manufacturing capability Completed construction of GMP manufacturing facility ...
June 15, 2021  •  Research Triangle Park, N.C.
StrideBio Expands Leadership Team with Accomplished Industry Executives
Newly created roles will support StrideBio’s operations across strategy, regulatory affairs, quality, and patient advocacy Research Triangle Park, N.C., June 15, 2021 – StrideBio, Inc., ...
April 27, 2021  •  Research Triangle Park, NC
StrideBio Appoints Deborah D. Ascheim, M.D. as Chief Medical Officer
Research Triangle Park, N.C., April 27, 2021 – StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment ...
April 14, 2021  •  Research Triangle Park, NC
StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies
StrideBio receives exclusive license to novel cross-species evolved AAV vectors and an enzymatic approach for neutralizing antibody evasion Master Sponsored Research Agreement will support collaborative ...
March 16, 2021  •  Research Triangle Park, NC
StrideBio Announces Closing of $81.5M Series B Financing
Proceeds to advance structure-guided AAV capsid engineering platform and pipeline of novel gene therapy candidates into the clinic, including four new wholly-owned programs Financing will ...